Assembly Biosciences (HAM:V7B) Institutional Ownership: 11.00% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:V7B Assembly Biosciences Inc HAM:V7B
20 GF Score
Price €21.50
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Institutional Ownership?

Assembly Biosciences HAM:V7B +0.94% 20 Institutional Ownership is 11.00% as of Aug. 05, 2026. GuruFocus rates HAM:V7B with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Assembly Biosciences's institutional ownership is 11.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Assembly Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Assembly Biosciences's Float Percentage Of Total Shares Outstanding is 74.43%.

Assembly Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Institutional Ownership Chart

Assembly Biosciences Historical Data

The historical data trend for Assembly Biosciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 7.60 8.70 8.30 7.34 6.94 6.82 6.80 6.14 10.91 11.00
HAM:V7B
20GF Score
Assembly Biosciences Inc HAM:V7B
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 11.00% mean?
Assembly Biosciences (HAM:V7B) has a Institutional Ownership of 11.00% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Institutional Ownership too high?
Assembly Biosciences' current Institutional Ownership is 11.00%. Overall, Assembly Biosciences has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Institutional Ownership compare to ZURA and ARVN?
Assembly Biosciences' Institutional Ownership of 11.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Institutional Ownership is 11.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (HAM:V7B) has a current Institutional Ownership of 11.00%. The current Institutional Ownership is 11.00%. Assembly Biosciences' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Assembly Biosciences (HAM:V7B), the current Institutional Ownership is 11.00% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges ASMB:USAV7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
20GF Score

Get the complete analysis for HAM:V7B

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.50
Price